Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats

Xenobiotica

Volumn 39, Issue 4, 2009, Pages 293-301

  Zhu, Q ^a   Liao, J ^b   Xie, L ^a   Wang, G J ^a   Liu, X D ^a  

^a Key Laboratory of Drug Metabolism and Pharmacokinetics   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antofloxacin; CYP1A2; Liver microsomes; Mechanism based inhibition; Physiological pharmacokinetics model

Indexed keywords

ANTOFLOXACIN; CYTOCHROME P450 1A2; LEVOFLOXACIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PHENACETIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; OFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER MICROSOME; MALE; NONHUMAN; RAT; ANIMAL; BIOLOGICAL MODEL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KINETICS; METABOLISM; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; KINETICS; MALE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; OFLOXACIN; PHENACETIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 66149122616     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802709428     Document Type: Article

References (31)

1. Andreas L, Jeroen B. 2002. Differences in caffenine and paraxanthine metabolism between human and murine CYP1A2. Biochem Pharmacol 63(12):2159-2167.
2. Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR. 1995. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 39(3):305-311.
3. Elliot VH, Paul AM. 2004. Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 135:298-311.
4. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. 2004. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 76(5):598-606.
5. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. 2000. Methadone, cipro- floxacin, and adverse drug reactions. Lancet 356(9274):2069-2070.
6. Hersh EV, Moore PA. 2004. Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 135(7):845.
7. Hiroshi I, Yasuhiro T, Shigetoshi K, Akira H, Tadashi W. 2005. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from evodia fruit extract. Drug Metab Pharmacokinet 20(1):34-45.
8. Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ. 2003. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 58(10):653-657.
9. Kingzig-Schippers M, Fuhr U, Zaigler M, Dammeyer J, Rüsing G, Labedzki A, Bulitta J, Sörgel F. 1999. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther 65(3):262-274.
10. Koboyashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T, Kuroiwa Y. 1998. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 45:361-368.
11. Kunii T, Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Inoue Y, Otani K. 2005. Interaction study between enoxacin and fluvoxamine. Therapeut Drug Monit 27(3):349-353.
12. Liu XQ, Zhao Y, Li D, Qian ZY, Wang GJ. 2003. Metabolism and metabolic inhibition of clinipine in human liver microsomes. Acta Pharmacologica Sinica 24(1):263-268.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with Folin phenol reagent. J Biol Chem 193:265-275.
14. Maesen FP, Teengs JP, Baur C, Davies BI, 1984. Quinolones and raised plasma concentrations of theophylline. Lancet ii(8401):530.
15. Nakamura H, Ohtsuka T, Enomoto H, Hasegawa A, Kawana H, Kuriyama T, Ohmori S, Kitada M. 2001. Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy. Ann Pharmacother 35(6):691-693.
16. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. 2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Disposit 29(10):1316-1324.
17. Pang XY, Xie L, Xu X, Liu HY, Liu L, Liu XD. 2007. Pharmacokinetics of antofloxacin in rats coadministered with non-steroidal anti-inflammatory drugs. Chin J New Drugs 16(8):600-603. [in Chinese]
18. Parker AC, Preston T, Heaf D, Kitteringham NR, Choonara I. 1994. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol 38(6):573-576.
19. Raaska K, Neuvonen PJ. 2000. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 56(8):585-589.
20. Richter T, Murdter TE, Heinkele G, Pleiss J, Tazel S, Schwab M, Eichelbaum E, Zanger UM. 2004. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308(1):189-197.
21. Ron EP. 1989. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 87(5):S76-S81.
22. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414-423.
23. Shiraki H, Guengerich FP. 1984. Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P-450 reductase and epoxide hydrolase. Archiv Biochem Biophys 235(1):86-96.
24. Silverman RB. 1988. Mechanism-based enzyme inactivation: chemistry and enzymology. Boca Raton, FL: CRC Press.
25. Tarrus E, Cami J, Roberts DJ, Spickett RG, Celdran E, Segura J. 1987. Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23(1):9-18.
26. Wijnands WJ, Vree TB, Van Herwaarden CL. 1986. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 22(6):677-683.
27. Xiao Y, Lu Y, Kang Z, Hou F, Wang S, Li T, Liu Y, Xia Y. 2008a. Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. Int J Clin Pharmacol Therapeutics 46(4):172-179.
28. Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Zhang M, Li T. 2008b. Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharmaceut Drug Disposit 29(3):167-172.
29. Xu X, Liu HY, Liu L, Xie L, Liu XD. 2008. The influence of a newly developed quinolone: antofloxacin. on CYP activity in rats. Eur J Drug Metab Pharmacokinet 33(1):1-7.
30. Ye H, Wu JM, Yang YS, Chen KX, Ji RY. 2002. Antibacterial activities of the dirivatives-YH54 and YH57 of levofloxacin in vitro. China Pharmacol Bull 18(1):112-113.
31. Zhang H, Fang Y, Wang SJ. 2005. Simultaneous determination of blood drug concentration of acetaminophen and phenacetin by HPLC. China Pharma 16(8):608. [in Chinese]